Medibio Corporate Health Extends Global Footprint Signing Contract with Jacobs Engineering
Jacobs, one of the world's largest engineering and environmental consultancy groups, has more than 70,000 employees globally
SYDNEY, Australia and MINNEAPOLIS, May 25, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company) (ASX:MEB) (OTCQB:MDBIF), a mental health technology company, today announced a significant contract for Medibio's Corporate Health product with Dallas, TX-based Jacobs Engineering across their Asia Pacific, Middle East, and European divisions.
Through the Mental Health Check-In, companies can offer employees an end-to-end mental health program, direct to their devices, to see how the mind and body are tracking. It's a personalized, private, and objective way to see the unseeable: mental health issues in the workplace.
Employees are provided the opportunity to confidentially check-in on their mental health and receive personalized confidential results from both an objective biometric screening in conjunction with a 12-minute subjective survey. Employers receive a dashboard providing de-identified, amalgamated data on the well-being of their workforce leveraging both the subjective and objective metrics. Employees then have the option to connect their wearable devices, such as Apple Watch, Garmin, and Fitbit, collect heart rate and sleep data.
The first-phase contract extends Medibio's engagement with Jacob's beyond Asia Pacific, to now encompass over 8,000 employees across Asia Pacific, India, the Middle East and Europe. The Check-In will be rolled out to Jacobs' European leadership team alongside the Asia Pacific and Middle Eastern workforces and is projected to generate first-stage revenue of approximately $50,000 for the initial four-week program. Services, including consultancy and delivery of ongoing mental health interventions and programs, will be billed as provided.
The correlation of ANS biometrics and mental health has been the focus of the company for over 20 years. Especially while sleeping, our bodies reflect our mental state through the performance of the autonomic nervous system. Medibio's technology platform detects dysfunction within the areas of the body regulated by the ANS, and through proprietary data processing and algorithms, the technology correlates these anomalies to different mental health conditions. It is a profound discovery that for the first time provides a tangible, objective understanding of mental health.
"We are thrilled to extend our pivotal agreement with Jacobs Engineering, a long-term supporter of Medibio and a leading corporation in driving the way mental health care is delivered to their employee base," said CEO and Managing Director Jack Cosentino. "By leveraging our proprietary technology, in conjunction with Jacobs' strong corporate advocacy, we look forward to establishing a long-term relationship to enable real change in the area of corporate mental health."
Jacobs Engineering Group is one of the world's largest engineering and environmental consultancy groups. With a reputation for innovation, performance, and a human centric approach to employment and consultancy they have sought out programs that align with their values and integrate with their culture. Jacobs currently employs over 70,000 employees in over 250 offices worldwide.
Patrick Hill, Sr. Vice President and General Manager Buildings, Infrastructure and Advanced Facilities at Jacobs said: "Our partnership with Medibio appears to have been hugely beneficial to date. Their analytical and evidence-based approach is a significant step forward for an organization like Jacobs that is looking to move from awareness to action, and from reaction to prevention. As a company that aims to puts its people first, we are delighted to be extending the Check-in to other parts of our global business."
This contract signed by Jacobs Engineering continues Medibio's rapidly expanding portfolio of global companies participating in the Mental Health Check-in including:
- Jacobs Engineering (U.S.)
- St. John of God Health Care (Australia's third-largest healthcare provider)
- Australian Football League (AFL)
- Rio Tinto
- Aurecon Jacobs Joint Venture for West Gate Tunnel Project
The Mental Health Check-in Campaign is the entry-level offering to Medibio's Corporate Health products and is rapidly positioning Medibio as the preeminent mental health technology and services provider offering comprehensive mental health solutions for businesses.
About Medibio Limited
Medibio (ASX:MEB) (OTCQB:MDBIF) is a mental health technology company that has pioneered the use of objective biometrics to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions. The company offers mental health solutions for business through its Corporate Health programs and is developing products to serve both the consumer and regulated healthcare provider markets. The company was founded in Australia, with offices located in Melbourne (Vic), Perth (WA), and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.
Jacobs leads the global professional services sector delivering solutions for a more connected, sustainable world. With $15 billion in fiscal 2017 revenue when combined with full-year CH2M revenues and a talent force of more than 77,000, Jacobs provides a full spectrum of services including scientific, technical, professional and construction- and program-management for business, industrial, commercial, government and infrastructure sectors. For more information, visit www.jacobs.com, and connect with Jacobs on LinkedIn, Twitter, Facebook and Instagram.
|Further Information:||Website: www.medibio.com.au|
T: 952-222-0551 ext. 208
T: +61 434 405 400
A video accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/dca9e5bd-b9a4-4500-9840-9530068038c8
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medibio Limited via Globenewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
AMG Advanced Metallurgical Group N.V. Announces Weekly Share Repurchase Program Transaction Details19.7.2019 21:00:00 CEST | Press release
Amsterdam, 19 July 2019 --- AMG Advanced Metallurgical Group N.V. ("AMG", EURONEXT AMSTERDAM: "AMG") reports the repurchases made under its share repurchase program announced on 8 April 2019 and effective from 9 April 2019. Information regarding the progress of the share repurchase program and the aggregate of the transactions (calculated on a daily basis) for the period 15 July 2019 through 19 July 2019 can be found in the bottom half of the table below. Further detailed information regarding both the progress of the share repurchase program and the overall trades made on a daily basis can be accessed via the Investors section of the Company’s website, or clicking the following link: https://amg-nv.com/investors/share-buyback/ Share Repurchase Program Overall progress Share Repurchase Program: Total Repurchase Amount in Shares 2,915,630 Cumulative Repurchase Amount EUR 63,511,098 Cumulative Quantity Repurchased 2,534,054 Cumulative Average Repurchase Price EUR 25.06 Start Date 9 April
Ossur Hf : Össur acquires College Park Industries19.7.2019 17:00:00 CEST | Press release
Reykjavik, 19 July 2019 Össur has signed an agreement to acquire College Park Industries, a global provider of lower and upper limb prostheses and supporting services. College Park has over 140 employees and is headquartered in Detroit, USA. Total sales amounted to USD 22 million in 2018. College Park will largely remain independent and continue to diligently serve its customer base, while allowing the combined entity to achieve strategic efficiencies. Össur is committed to growing the College Park brand over the coming years both in the United States and international markets. Together, both companies will be well-positioned to enhance their offerings in both lower and upper limb prosthetics. With this acquisition, Össur hopes to support College Park’s focus on the lower active population and further strengthen its established presence in the upper limb arena. Mutual access to technology and products will enable a more comprehensive product and service offering to customers around the
Banks net position in the Riksbank19.7.2019 16:47:00 CEST | Press release
JUL 19, 2019 SEK MILLION LENDING BORROWING 277
Norsk Hydro: PÅMINNELSE: Invitasjon - Presentasjon av Hydros resultat for andre kvartal 201919.7.2019 14:43:00 CEST | Pressemelding
Hydros resultat for andre kvartal 2019 blir offentliggjort tirsdag 23. juli 2019 kl. 07.00. Kvartalsrapporten og presentasjonsmaterialet blir samtidig gjort tilgjengelig på www.hydro.com. Presentasjon i Oslo Det blir holdt en kombinert analytikerpresentasjon og pressekonferanse ved Hydros hovedkontor i Drammensveien 260, Oslo, samme dag, kl. 08.30. Resultatet blir presentert av konsernsjef Hilde Merete Aasheim og konserndirektør for Økonomi og finans Eivind Kallevik. Hele presentasjonen kan sees direkte på web-TV. For påmelding, vennligst send mail til email@example.com. I tillegg til web-TV, hvor det vil være mulig å stille spørsmål skriftlig, vil det også være mulig å ringe inn (ikke mulig å stille spørsmål over telefon). Du melder deg på denne telefonkonferansen ved å ringe: Norge +47 2100 2610 UK +44 (0)330 336 9125 USA +1 929-477-0324 Sverige +46 (0)8 5033 6574 Brasil +55 11 3181 5427 Tyskland +49 (0)89 20303 5709 Kode: 3104804 Q&A / Telefonkonferanse Det blir holdt en telefonkonferans
Norsk Hydro: REMINDER: Invitation - Hydro’s second quarter results 201919.7.2019 14:43:00 CEST | Press release
Hydro's second quarter results 2019 will be released at 07:00 CEST (01:00 AM EDT, 06:00 UK time), on Tuesday July 23, 2019. The quarterly report and presentation slides will be available on www.hydro.com at the same time. Presentation in Oslo Hydro will host a combined analyst and press conference, in English, at its corporate headquarters at Drammensveien 260, Oslo, at 08:30 CEST the same day. The presentation will be held by President and CEO Hilde Merete Aasheim and CFO Eivind Kallevik and can also be seen on web TV. To attend the presentation in Oslo, please register by sending a mail to firstname.lastname@example.org. In addition to the webcast, where it will be possible to ask questions in writing, it will also be possible to dial in (not possible to ask questions over the phone). Dial-in numbers for this conference call are: Norway +47 2100 2610 UK +44 (0)330 336 9125 USA +1 929-477-0324 Sweden +46 (0)8 5033 6574 Brazil +55 11 3181 5427 Germany +49 (0)89 20303 5709 Confirmation Code: 3104804 Q&A
Sunstone Life Science Ventures invests in Karolinska Development's portfolio company Forendo Pharma19.7.2019 14:00:00 CEST | Pressemelding
STOCKHOLM – July 19, 2019. Karolinska Development's portfolio company Forendo Pharma announces today that Sunstone Life Science Ventures joins the existing international investor syndicate and has made a EUR 5 million investment in Forendo Pharma. Claus Andersson, General Partner from Sunstone, joins Forendo Pharma’s Board of Directors. With the investment, Sunstone joins the existing international investor syndicate comprising Novo Seeds, Karolinska Development, Innovestor, Novartis Venture Fund, M Ventures and Vesalius Biocapital Partners. The new financing will enable Forendo Pharma to progress its lead endometriosis program, FOR-6219, an HSD17B1 enzyme inhibitor, into the next phase of clinical studies after the successful completion of its Phase 1a study earlier this year. Endometriosis is a chronic condition that affects many women of reproductive age and causes repeated pain symptoms, infertility and impaired quality of life. Currently available treatments for endometriosis have